Last updated: January 26, 2023
Sponsor: Wuerzburg University Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Rash
Shingles
Treatment
N/AClinical Study ID
NCT05705180
10.940-3.22_VXSS-218827
Ages 18-90 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Group 1, retrospective (samples already stored, CoVaKo study cohort): healthy (n=420) Group 2, prospective (samples to be recruited, CoVaKo study cohort): healthy (n=180)
- Age 18-90 years, stratified into <60 and ≥60 years
- at least 2 COVID-19-mRNA vaccinations as equivalent to primary immunization and thethird and/or fourth dose considered as booster, as recommended for all individuals >12years (third dose) and for risk groups, medical staff, nursing home residents (fourthdose) in Germany Only individuals naive for SARS-CoV-2 (negative N-specific andS-specific-IgG antibody status, no history of PCR+ swab) before COVID-19 vaccinationwill be included.
Exclusion
Exclusion Criteria:
- High-dose glucocorticoids >10 mg/day
- Immunosuppressive therapy
- Biologics or immunomodulators
- Transplantation
- Cancer
- Autoimmunity
- RZV after COVID-19 vaccination
- COVID-19 PCR+ before COVID-19 vaccination
- Other types of COVID-19 vaccines than mRNA vaccines
Study Design
Total Participants: 600
Study Start date:
December 01, 2022
Estimated Completion Date:
December 01, 2024
Connect with a study center
University Hospital Wuerzburg
Wuerzburg, Bavaria 97080
GermanyActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.